TrialArthritis & rheumatology (Hoboken, N.J.)2021

Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.

Iain B McInnes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.